| SANOFI Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136026 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to compounds of the general formula (I) where: R | 05-31-2012 |
| 20120135958 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an | 05-31-2012 |
| 20120129864 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME - The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C | 05-24-2012 |
| 20120129830 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds of the general formula (I) where: R | 05-24-2012 |
| 20120127823 | HIGH-PRESSURE HOMOGENIZATION WITH A SILICON NITRIDE VALVE - The invention relates to the use of a homogenisation valve that comprises a flap gate ( | 05-24-2012 |
| 20120122947 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 05-17-2012 |
| 20120122774 | LONG-ACTING FORMULATIONS OF INSULINS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 05-17-2012 |
| 20120115906 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to compounds of the formula (I), where: R | 05-10-2012 |
| 20120115898 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to a compound of formula (I), where: R | 05-10-2012 |
| 20120115846 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. - The subject matter of the invention is quinazolinedione derivatives of formula (I), methods for obtaining same and therapeutic uses thereof, such as cancer, diabetes, muscle diseases, bone diseases, cardiovascular diseases, central nervous system diseases, peripheral nervous system diseases, inter alia. | 05-10-2012 |
| 20120115809 | USE OF AN ACYLATED OCTASACCHARIDE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the use of the octasaccharide of formula (I), wherein Ac represents an acetyl group: | 05-10-2012 |
| 20120115806 | Antitumor Combination Including Cabazitaxel and Capecitabine - The invention relates to a method of treatment of metastatic breast cancer in a patient progressing after a previous anthracycline and/or taxane treatment, said method comprising administering to said patient a combination of antitumor agents comprising cabazitaxel and capecitabine, wherein each of said antitumor agents, independently, may be in the form of a base, in the form of a pharmaceutically acceptable acid salt or in the form of a hydrate or solvate. | 05-10-2012 |
| 20120108641 | ANTITUMOR COMBINATION INCLUDING AVE8062 AND SORAFENIB - Combinations comprising AVE8062 and sorafenib are provided which are effective in the treatment of cancers, more particularly of solid tumours. | 05-03-2012 |
| 20120108544 | ACYLATED DECASACCHARIDES AND THEIR USE AS ANTITHROMBOTIC AGENTS - The instant invention relates to decasaccharides of formula (I): | 05-03-2012 |
| 20120108543 | SULFATED HEPTASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the heptasaccharide of formula (I): | 05-03-2012 |
| 20120108542 | SULFATED OCTASACCHARIDE AND ITS USE AS ANTITHROMBOTIC AGENT - The instant invention relates to the octasaccharide of formula (I): | 05-03-2012 |
| 20120108541 | ACYLATED 1,6-ANHYDRO DECASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: | 05-03-2012 |
| 20120101150 | USE OF VGII3 ACTIVITY MODULATOR FOR THE MODULATION OF ADIPOGENESIS - The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided. These methods, compositions and molecules can be useful to modulate adipogenesis and thus treat obesity and related disorders. | 04-26-2012 |
| 20120096571 | EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction. | 04-19-2012 |
| 20120095216 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES - A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: | 04-19-2012 |
| 20120095040 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds of the general formula (I) where: R | 04-19-2012 |
| 20120094864 | EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR - The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor. | 04-19-2012 |
| 20120083608 | PROCESS FOR THE PREPARATION OF [4-(2-CHLORO-4- METHOXY-5-METHYLPHENYL)-5-METHYL-THIAZOLO-2-YL]-[2-CYCLOPROPYL-1-(3-FLUOR- O-4-METHYLPHENYL)-ETHYL]-AMINE - The present invention is a process for the preparation of [4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-thiazolo-2-yl]-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-ethyl]-amine as set forth in formula (I) | 04-05-2012 |
| 20120077995 | PROCESS FOR THE PRODUCTION OF DRONEDARONE INTERMEDIATES - A process for the production of Dronedarone intermediates of the formula (I), by acylation of 2-(2-hydroxy-5-nitrophenyl)-1-(4-methoxyphenyl)-ethanone, subsequent treatment of the ester with bases and a zeolite (alumosilicate) catalyst and optional subsequent demethylation. This process can be used for the production of Dronedarone. | 03-29-2012 |
| 20120071536 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to N-[(2-aza-bicyclo[2.2.1]hex-1-yl)-aryl-methyl]-benzamide derivatives of the general formula (I) where: R is a hydrogen atom or a (C | 03-22-2012 |
| 20120065411 | PROCESS FOR THE PRODUCTION OF BENZOFURANS - A process for the production of 2-alkyl-3-aroyl-5-nitrobenzofurans by acylation of 2-(2-hydroxy-5-nitrophenyl)-1-aryl-ethanones and subsequent treatment of the esters with combinations of bases and proton acids or Lewis acids. This process can be used for the production of Dronedarone. Furthermore, novel intermediates for the manufacture of Dronedarone are provided. | 03-15-2012 |
| 20120065234 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF - The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 03-15-2012 |
| 20120065078 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES - The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease. | 03-15-2012 |
| 20120059165 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF - A production method of an optically active 2-{4-(5-substituted-oxadiazolyl) phenyl}morpholine which is useful as an intermediate for synthesizing a pharmaceutical agent is provided and the method comprises the following steps 1) to 4): 1) reacting a bromophenylmorpholine with a hexacyanoferrate(II) or a hydrate thereof at a temperature of from 110° C. to 140° C. in a reaction mixture comprising a Na | 03-08-2012 |
| 20120058987 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES - The subject matter of the present invention is the use of compounds of formula (I) in the form of a base, a hydrate or a solvate, or of mixtures thereof, as a medicament or for preparing a medicament intended for the treatment and/or prevention of disorders associated with the central nervous system (abbreviated to CNS) and/or associated with the peripheral nervous system (abbreviated to PNS). | 03-08-2012 |
| 20120046241 | DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL IMPAIRMENT - This invention relates to a dose of 10 mg of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment. | 02-23-2012 |
| 20120041189 | PENTASACCHARIDE CRISTALLISE, SON PROCEDE D'OBTENTION ET SON UTILISATION POUR LA PREPARATION D'IDRAPARINUX - The Invention relates to the methyl pentasaccharide O-2,3,4-tri-O-methyl-α-D-glucopyranosyl-(1→4)-O-2,3-di-O-methyl-β-D-glucopyranosyluronic acid-(1→4)-O-α-D-glucopyranosyl-(1→4)-O-2,3-di-O-méthyl-α-L-idopyranosyluronic acid-(1→4)-O-α-D-glucopyranose in crystallised form, to a method for obtaining the same and to the use thereof for the preparation of idraparinux. | 02-16-2012 |
| 20120040996 | 3-BENZOFURANYL-INDOL-2-ONE DERIVATIVES SUBSTITUTED AT THE 3 POSITION, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position and of the formula (I) where R1, R2, R3, R4, R5 and n are such as defined in claim | 02-16-2012 |
| 20120040987 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS - The invention relates to novel products of the formula (I) where: (II) is a single or double bond; Rb is a hydrogen or fluorine atom; Ra is a NH-Rc radical in which Rc is an optionally substituted heterocycloalkyl, aryl, heteroaryl or -alkylcycloalkyl radical; X is S, SO, or SO2; A is NH or S; W is H, alkyl, or COR with R being cycloalkyl; alkyl; alkoxy; O-phenyl; —O— (CH2)n-phenyl with n=1 to 4; or NR1R2 with R1 being H or alk and R2 is H, cycloalkyl or alkyl; or R1, R2 form a cycle together with N optionally containing O, S, N and/or NH; all of said radicals being optionally substituted; wherein said products can be in any isomer or salt form, and can be used as drugs, in particular as MET inhibitors. | 02-16-2012 |
| 20120040984 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof. | 02-16-2012 |
| 20120029027 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME - The invention relates to a compound of the general formula (I), where: R is a hydrogen atom or a group selected from the (C | 02-02-2012 |
| 20120022099 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE - The present disclosure is directed to solid forms of the compound of formula (I): | 01-26-2012 |
| 20120022039 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS - The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according to the invention or derivative thereof, and to the use of the substituted indanes according to the invention and to derivatives thereof as MCH antagonists. | 01-26-2012 |
| 20120015936 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS - The invention relates to substituted tetrahydronaphthalenes, to derivatives thereof, to physiologically acceptable salts thereof, to physiologically functional derivatives, to the production thereof, to drugs containing at least one substituted tetrahydronaphthalene according to the invention or derivative thereof, and to the use of the substituted tetrahydronaphthalenes according to the invention and to derivatives thereof as MCH antagonists. | 01-19-2012 |
| 20120010409 | IMPROVED CHEMICAL SYNTHESIS OF DIAZAINDOLES BY CHICHIBABIN CYCLIZATION - An improved synthesis method for making diazaindoles using a Chichibabin cyclization is disclosed. In particular, this method is useful for making the compound of Formula I. | 01-12-2012 |
| 20120010241 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF - The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R′1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A′), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs. | 01-12-2012 |
| 20120010208 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to the general formula (I) in which R | 01-12-2012 |
| 20120005128 | METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION - The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps:
| 01-05-2012 |
| 20120004294 | ANTITUMOR COMBINATION COMBINING AVE8062 AND DOCETAXEL - The invention relates to a sequential antitumor combination of AVE8062, or a salt thereof, and docetaxel, characterized in that AVE8062 is administered to a patient in a dose of 10 to 50 mg/m2, and then, on a different day of the week, preferably after a 24-hour interval, docetaxel is administered in a dose of 50 to 120 mg/m2. | 01-05-2012 |
| 20120004187 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to spirocyclically substituted 1,3-propane dioxide derivatives, and to the physiologically compatible salts thereof. | 01-05-2012 |
| 20120004167 | (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS - The invention relates to substituted (2-aryloxyacetylamino)phenylpropionic acid derivatives, and to the physiologically acceptable salts thereof. | 01-05-2012 |
| 20120004166 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to aryloxyalkylene-substituted hydroxyphenylhexynoic acid derivatives, and to physiologically compatible salts thereof. | 01-05-2012 |
| 20120004165 | HETEROCYCLICALLY SUBSTITUTED METHOXYPHENYL DERIVATIVES WITH AN OXO GROUP, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS - Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments | 01-05-2012 |
| 20120000806 | METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION - The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps:
| 01-05-2012 |
| 20110319381 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to a compound of the general formula (I) in which R | 12-29-2011 |
| 20110313168 | METHOD FOR PREPARING ACTIVATED ESTERS - The invention relates to a method for preparing an activated ester of the formula (I), where R is a (C | 12-22-2011 |
| 20110312972 | SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to disubstituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of the general formula (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are such as defined in claim | 12-22-2011 |
| 20110312874 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE - The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of screening a modulator of the TRPC channel or an inactivating mutant thereof. | 12-22-2011 |
| 20110306566 | TOPICAL SKIN TREATMENT KITS - This invention relates to benzoyl peroxide products for skin treatment, and more particularly to a kit containing a benzoyl peroxide product and a topical moisturizing product. In one embodiment the kit contains BenzaClin® brand clindamycin-benzoyl peroxide gel and Viscontour® brand hyaluronic acid serum. | 12-15-2011 |
| 20110306563 | MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C | 12-15-2011 |
| 20110306553 | METHODS AND USES INVOLVING HEME BINDING PROTEIN 1 - The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular disease, the use of HEBP-1 for the detection of a component of eNOS signal transduction, and the use of HEBP1 for the regulation of eNOS promoter activity. | 12-15-2011 |
| 20110301148 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: | 12-08-2011 |
| 20110301107 | DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to derivatives of morphine-6-glucuronide of formula (I) | 12-08-2011 |
| 20110301081 | LONG-ACTING FORMULATIONS OF INSULINS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 12-08-2011 |
| 20110297563 | METHODS FOR REDUCING RISK - Methods for limiting and controlling the distribution of dronedarone to patients whose use of the drug might present an unacceptable risk. | 12-08-2011 |
| 20110294788 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS - The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF. | 12-01-2011 |
| 20110275820 | SYNTHESIS OF MORPHINE-6-GLUCURONIDE OR ONE OF THE DERIVATIVES THEREOF - The disclosure relates to a method for preparing morphine-6-glucuronide or one of the deritives thereof comprising reacting a compound of formula (I): | 11-10-2011 |
| 20110275580 | BICYCLIC DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to compounds of formula (I): | 11-10-2011 |
| 20110257213 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 10-20-2011 |
| 20110257190 | CRYSTALLINE FORMS - The disclosure relates to crystalline forms of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenyl]-propan-2-ol, characterized by physico-chemical data described herein. | 10-20-2011 |
| 20110251225 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): | 10-13-2011 |
| 20110251219 | TREATMENT FOR GLOMERULONEPHRITIS WITH 2-[4-(7-ETHYL-5H-PYRROLO[2,3-B]PYRAZIN-6-YL)PHENYL]PROPAN-2-OL - A treatment for glomerulonephritis, and other renal dysfunctions using a compound of Formula I is disclosed. | 10-13-2011 |
